These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 22974412

  • 1. Effect of metformin glycinate on glycated hemoglobin A1C concentration and insulin sensitivity in drug-naive adult patients with type 2 diabetes mellitus.
    González-Ortiz M, Martínez-Abundis E, Robles-Cervantes JA, Ramos-Zavala MG, Barrera-Durán C, González-Canudas J.
    Diabetes Technol Ther; 2012 Dec; 14(12):1140-4. PubMed ID: 22974412
    [Abstract] [Full Text] [Related]

  • 2. Anti-hyperglycemic effects of propolis or metformin in type 2 diabetes mellitus.
    Ochoa-Morales PD, González-Ortiz M, Martínez-Abundis E, Pérez-Rubio KG, Patiño-Laguna ADJ.
    Int J Vitam Nutr Res; 2023 Dec; 93(6):498-506. PubMed ID: 35965421
    [Abstract] [Full Text] [Related]

  • 3. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus.
    Kothny W, Foley J, Kozlovski P, Shao Q, Gallwitz B, Lukashevich V.
    Diabetes Obes Metab; 2013 Mar; 15(3):252-7. PubMed ID: 23039321
    [Abstract] [Full Text] [Related]

  • 4. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
    Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A.
    Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
    [Abstract] [Full Text] [Related]

  • 5. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF.
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [Abstract] [Full Text] [Related]

  • 6. Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control.
    Rosenstock J, Rood J, Cobitz A, Huang C, Garber A.
    Diabetes Obes Metab; 2006 Nov; 8(6):643-9. PubMed ID: 17026488
    [Abstract] [Full Text] [Related]

  • 7. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin.
    Mudaliar S, Henry RR, Boden G, Smith S, Chalamandaris AG, Duchesne D, Iqbal N, List J.
    Diabetes Technol Ther; 2014 Mar; 16(3):137-44. PubMed ID: 24237386
    [Abstract] [Full Text] [Related]

  • 8. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea.
    Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M.
    Diabetes Care; 2006 Jun; 29(6):1282-7. PubMed ID: 16732009
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V, Del Prato S, Araga M, Kothny W.
    Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
    [Abstract] [Full Text] [Related]

  • 12. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.
    Cusi K, Consoli A, DeFronzo RA.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4059-67. PubMed ID: 8923861
    [Abstract] [Full Text] [Related]

  • 13. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
    Derosa G, Franzetti IG, Querci F, Carbone A, Ciccarelli L, Piccinni MN, Fogari E, Maffioli P.
    Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
    [Abstract] [Full Text] [Related]

  • 14. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ.
    Diabetes Obes Metab; 2012 Jun; 14(6):565-74. PubMed ID: 22356132
    [Abstract] [Full Text] [Related]

  • 15. Retrospective chart review of children with type 2 diabetes mellitus evaluating the efficacy of metformin vs. insulin vs. combination insulin/metformin.
    Meyer SL, Hoffman RP.
    South Med J; 2011 Oct; 104(10):684-8. PubMed ID: 21941156
    [Abstract] [Full Text] [Related]

  • 16. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes.
    Natali A, Baldeweg S, Toschi E, Capaldo B, Barbaro D, Gastaldelli A, Yudkin JS, Ferrannini E.
    Diabetes Care; 2004 Jun; 27(6):1349-57. PubMed ID: 15161787
    [Abstract] [Full Text] [Related]

  • 17. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.
    Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE, Sitagliptin 036 Study Group.
    Diabetes Care; 2007 Aug; 30(8):1979-87. PubMed ID: 17485570
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Charbonnel B, Karasik A, Liu J, Wu M, Meininger G, Sitagliptin Study 020 Group.
    Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
    [Abstract] [Full Text] [Related]

  • 19. Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes.
    Preiss D, Dawed A, Welsh P, Heggie A, Jones AG, Dekker J, Koivula R, Hansen TH, Stewart C, Holman RR, Franks PW, Walker M, Pearson ER, Sattar N, DIRECT consortium group.
    Diabetes Obes Metab; 2017 Mar; 19(3):356-363. PubMed ID: 27862873
    [Abstract] [Full Text] [Related]

  • 20. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
    Bosi E, Ellis GC, Wilson CA, Fleck PR.
    Diabetes Obes Metab; 2011 Dec; 13(12):1088-96. PubMed ID: 21733058
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.